TIDMAKR
RNS Number : 9386R
Akers Biosciences, Inc.
06 March 2019
March 6, 2019
Akers Biosciences, Inc.
Result of Special Meeting of Shareholders
Cancellation of Admission of Common Stock to Trading on AIM
Form 8-K Filing
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers Bio"), a developer of rapid health information
technologies, announces that, at the Special Meeting of
Shareholders held yesterday, the Company's shareholders approved
the special resolution to cancel the admission of the Company's
common stock of no par value (the "Common Stock") to trading on
AIM, a market operated by London Stock Exchange plc (the "AIM
Cancellation").
Accordingly, the last day of dealings in the Company's Common
Stock on AIM will be March 28, 2019 and, as detailed in the
Company's DEF 14A filing on February 5, 2019 (the "DEF 14A") and
its announcement on February 6, 2019 (the "RNS Announcement"),
trading in the Company's Common Stock on AIM will cease, and the
AIM Cancellation will become effective, at 7.00 a.m. (GMT) on March
29, 2019. The AIM Cancellation is subject to a dealing notice, as
defined in the AIM Rules for Companies, being issued by London
Stock Exchange plc. The AIM Cancellation has no effect on the
listing of the Company's Common Stock on NASDAQ Capital Market
which will continue as usual.
Shareholders whose shares are registered on the Company's Jersey
(Channel Islands) Branch Register, including holders of Depositary
Interests, who have not already done so are encouraged to read the
DEF 14A or RNS Announcement (available within the US SEC Filings
and UK RNS Announcements sections respectively of the Company's
website at www.akersbio.com) for detailed information regarding the
effects of the AIM Cancellation.
The Company has filed a Form 8-K with the U.S. Securities and
Exchange Commission in connection with the Special Meeting of
Shareholders. The Form 8-K is available to view on Akers Bio's
website at www.akersbio.com or on www.sec.gov and appears in full
in the appendix below.
Inquiries:
Akers Biosciences, Inc.
Howard R. Yeaton, Chief Executive Officer and Interim Chief
Financial Officer
Tel. +1 856 848 8698
investors@akersbio.com
finnCap (UK Nominated Adviser and Broker)
Ed Frisby / Scott Mathieson (Corporate Finance)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7390 0234
Email: akers@vigocomms.com
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high-volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com.
Cautionary Note Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements reflect the Company's expectations about its future
operating results, performance and opportunities that involve
substantial risks and uncertainties. Such statements may include,
without limitation, statements with respect to the Company's plans,
compliance with the requirements of various regulatory agencies and
certain NASDAQ Stock Market listing rules, objectives, projections,
expectations and intentions and other statements identified by
words such as "projects," "may," "will," "could," "would," "should,
" "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "potential" or similar expressions, as they relate to the
Company, its subsidiaries, or its management. These statements are
based upon the current beliefs and expectations of the Company's
management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the
Securities and Exchange Commission. Actual results, performance,
prospects, and opportunities to may differ materially from those
set forth in, or implied by, the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
APPENDIX - FORM 8-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 5,
2019
AKERS BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
New Jersey 001-36268 22-2983783
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
201 Grove Road
Thorofare, New Jersey USA 08086
(Address of principal executive offices, including zip code)
(856) 848-8698
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
Company under any of the following provisions:
[ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
]
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933
(--230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (--240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. [
]
Item 5.07. Submission of Matters to a Vote of Security
Holders.
On March 5, 2019, Akers Biosciences, Inc. (the "Company") held a
special meeting of shareholders (the "Special Meeting"). The number
of shares of common stock of the Company (the "Common Stock")
entitled to vote at the Special Meeting was 12,482,708. The number
of shares of Common Stock present or represented by valid proxy at
the Special Meeting was 7,650,410. Greater than 33.34% of the
shares of Common Stock outstanding and entitled to vote at the
Special Meeting were present in person or by proxy, thereby
constituting a quorum. All matters submitted to a vote of the
Company's stockholders at the Special Meeting were approved. The
voting results reported below are final.
The following is a tabulation of the voting on the proposal
presented at the Special Meeting:
Proposal 1: To approve the cancellation of the admission of the
Company's common stock of no par value to trading on AIM, a market
operated by London Stock Exchange, and that the directors and
officers of the Company be authorized to take all steps which are
necessary or desirable in order to effect such cancellation (the
"Cancellation Proposal").
Shares Voted For Shares Against Shares Abstaining
---------------- -------------- -----------------
7,408,643 171,463 70,304
On the basis of the above votes, the Cancellation Proposal was
adopted. With the approval of the Cancellation Proposal, it is
anticipated that trading in the Common Stock on AIM will cease, and
the delisting will take effect, from 7.00 a.m. (GMT) on March 29,
2019. Upon the delisting becoming effective, finnCap Limited will
cease to be the nominated adviser and broker to the Company in the
UK and the Company will no longer be required to comply with the
rules and corporate governance requirements to which companies
admitted to trading on AIM are subject, including the AIM Rules.
The Company will remain subject to the rules and corporate
governance requirements promulgated by the SEC and NASDAQ.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
AKERS BIOSCIENCES, INC.
Date: March 5, 2019 By: /s/ Howard R. Yeaton
-----------------------
Howard R. Yeaton
Chief Executive Officer
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMUGUMUWUPBGMA
(END) Dow Jones Newswires
March 06, 2019 02:00 ET (07:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024